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SUMMARY 
 
Bell’s palsy is facial nerve paralysis of unknown cause. Left untreated, 
70–75% of patients make a full recovery. 
 
Early treatment with prednisolone increases the chance of complete 
recovery of facial function to 82%. Eleven people need to be treated for 
one extra complete recovery at six months. 
 
There may be benefit in adding an antiviral drug to prednisolone in 
some cases. Additional research is needed on this treatment.  
 
The palsy may leave the surface of the eye exposed. Early eye 
protection with lubrication and a patch is crucial to prevent long-term 
complications. 
 
 
  
Formatted
Articles in Progress/Sullivan/Changes after EEC 315 (JD) 3 
 
Introduction 
 
Bell’s palsy, also called idiopathic facial paralysis, is defined as an acute 
onset, isolated, unilateral, lower motor neurone facial weakness. The 
reported annual incidence varies in different parts of the world with 
estimates varying between 11 and 40 per 100 000 people.1 It is more 
common in people with diabetes.2  
 
Aetiology 
 
The underlying pathophysiology observed in post-mortem cases of Bell’s 
palsy is vascular distension, inflammation and oedema with ischaemia of 
the facial nerve. The aetiology remains unclear. Various causes have been 
proposed including viral, inflammatory, autoimmune and vascular. 
However, reactivation of herpes simplex virus or herpes zoster virus from the 
geniculate ganglion is suspected to be the most likely cause.3,4 Despite 
advances in neuroimaging, the diagnosis of Bell’s palsy is mainly clinical.5 
 
Clinical features (see Box) 
 
There are several conditions to consider in the differential diagnosis: 
 
• upper motor neurone lesion – based on innervation, absence of 
forehead wrinkling is a reliable way of differentiating Bell’s palsy from 
an upper motor neuron lesion  
• herpes zoster oticus (Ramsay Hunt syndrome)  
• rarer causes including otitis media, HIV infection, sarcoidosis, 
autoimmune disorders or tumours of the parotid gland. 
 
Complications 
 
In addition to ocular problems, the complications of Bell's palsy include: 
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• motor synkinesis (involuntary movement of muscles occurring at the 
same time as deliberate movement, for example involuntary mouth 
movement during voluntary eye closure)  
• crocodile tears (tears when eating due to misdirection of regenerating 
gustatory fibres destined for the salivary glands, so that they become 
secretory fibres to the lacrimal gland and cause ipsilateral tearing while 
the patient is eating) 
• incomplete recovery 
• contracture of facial muscles 
• reduction or loss of sensation of taste 
• problems with dysarthria due to facial muscle weakness. 
 
Prognosis 
 
The severity of symptoms of Bell’s palsy varies from mild weakness to severe 
paralysis, but the prognosis is generally good. The Copenhagen Facial Nerve 
Study found that around 71% of patients recover normal function without 
treatment. Around 13% are left with slight weakness and around 4% with 
severe weakness resulting in major facial dysfunction. Contracture of the 
facial muscles on the affected side was found in 17% and associated 
movements were found in 16%.6 Scoring systems such as House 
Brackmann scale used in randomised controlled trials and systematic 
reviews may be helpful to monitor progress.7  
 
Although the study was underpowered to detect differences in outcome in 
patients with different degrees of baseline severity Tthe recovery rate in one 
randomised controlled trial was significantly higher for those with moderate 
severity at onset compared to those with severe Bell’s palsy. Recovery was 
90% with those moderately affected. It was 78% in those severely affected8. 
The interaction was non-significant.8  
The frequency of review depends on the individual patient and the severity of 
their symptoms. If there is no improvement after a month the patient should 
Articles in Progress/Sullivan/Changes after EEC 315 (JD) 5 
 
be referred. A referral is also indicated if there is only partial recovery after 
6–9 months.  
 
The palsy recurs in 7% of patients, with equal incidence of ipsilateral and 
contralateral recurrence. There are insufficient data on whether treatment 
affects the rate of recurrence. 
 
Management 
 
The treatment of Bell’s palsy aims to speed recovery and reduce long-term 
complications. An inability to close the eye on the affected side increases the 
risk of corneal complications. Eye protection is crucial so an eye patch and 
lubricants are used to prevent drying of the cornea. Eye drops, such as 
hypromellose drops should be applied for lubrication during the day and 
ointment at night. In severe cases, the eye may have to be taped or partially 
sutured shut. 
  
Drug therapy 
 
The treatments considered for Bell’s palsy include oral corticosteroids 
(prednisolone) and antiviral drugs. Although the aetiology of Bell’s palsy is 
uncertain, it is known that inflammation and oedema of the facial nerve are 
responsible for the symptoms. Corticosteroids have therefore been used for 
their anti-inflammatory effect.  
 
Corticosteroids 
 
The maximum benefit is seen when steroids are commenced within 72 
hours of the onset of symptoms. There is no optimum regimen, but in adults 
50–60 mg prednisolone daily for 10 days has been commonly used.6,9 
Prednisolone has been used at a dose of 1 mg/kg/day up to a maximum of 
80 mg in some studies. Doses of more than 120 mg/day have been used 
safely in patients with diabetes.10 
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In a randomised controlled trial the recovery rate at nine months with 
prednisolone was 94%. It was 81.6% in patients who did not receive 
prednisolone.7 
 
A systematic review of trials that used prednisolone showed that at six 
months 17% of patients had incomplete recovery compared with 28% of 
patients who received no treatment. There was also a significant reduction 
in motor synkinesis in those who received prednisolone. There was no 
significant reduction in cosmetically disabling sequelae.11 
 
Antiviral drugs 
 
The antiviral drugs used in trials were aciclovir (400 mg five times daily for 
five days) or valaciclovir (1000 mg/day for five days),12 There is currently no 
evidence to support the use of either antiviral drug on its own,13,14 and there 
is uncertainty regarding the benefit of adding them to corticosteroids.  
 
Combination therapy 
 
A randomised controlled trial found that at nine months of diagnosis, facial 
function had recovered in 94.4% of patients who took prednisolone alone, 
85.4% of those who took aciclovir alone and 92.7% of those who received 
both. There were no serious adverse effects in any group. The study 
concluded that early treatment with prednisolone alone increases the 
likelihood of complete recovery and there was no additional benefit of 
treatment with aciclovir alone or combining with prednisolone.7 However, a 
systematic review also found that treatment with prednisolone reduced the 
chances of incomplete recovery but using an antiviral drug had an 
additional benefit.15 
 
There have been several studies looking at the benefit of antiviral drugs with 
or without prednisolone. A randomised prospective study found that a 
Articles in Progress/Sullivan/Changes after EEC 315 (JD) 7 
 
combination of an antiviral and a steroid was more effective in treating 
severe to complete Bell’s palsy than steroid alone.16 A guideline development 
group found that there was low-quality evidence of benefit from adding 
antivirals. Patients who are offered them in addition to corticosteroids 
should be counselled that the increase in recovery is less than 7%.17 
  
A Cochrane review in 2015 found that antivirals combined with 
corticosteroids improved rates of incomplete recovery compared with 
corticosteroids alone, but this was not significant and the evidence was low-
quality. There was moderate-quality evidence that the combination reduced 
long-term sequelae such as excessive tear production and synkinesis. The 
outcome for patients who received corticosteroids alone was significantly 
better than for those who received antivirals alone. Antiviral drugs alone had 
no benefit over placebo. None of the treatments had significant differences in 
adverse effects, but the evidence was again of low quality.13  
 
The optimum management of children with Bell’s palsy is also unknown. A 
major trial (BellPIC) in Australia is addressing this question.18 
 
Adverse effects of treatment 
 
Treatment courses are short, but can cause adverse effects. 
 
Prednisolone: 
 
• caution use in immunosuppression and sepsis 
• can induce or worsen peptic ulcer disease 
• hyperglycaemia especially in diabetics, however higher doses may 
be required in diabetes 
• malignant hypertension 
• hepatic and renal dysfunction. 
 
Antiviral drugs: 
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• nausea and vomiting 
• abdominal pain 
• diarrhoea 
• very rarely – hepatitis and jaundice 
• neurological reactions – dizziness, convulsions (more common with 
higher doses). 
 
Non-drug therapy 
 
Physical therapies including tailored facial exercises, acupuncture to 
affected muscles, massage, thermotherapy and electrical stimulation have 
been used to hasten recovery. However, evidence for any significant benefit 
is lacking. A Cochrane review concluded from poor quality evidence that 
tailored facial exercises can help improve facial function, mainly for 
moderate paralysis and chronic cases. Early facial exercise may reduce 
recovery time and long-term paralysis and chronic cases.19 
  
Surgical treatment to free the facial nerve has been considered. There is very 
low-quality evidence for this procedure.20-22 
  
Conclusion 
 
The symptoms of Bell’s palsy vary from mild to severe. The aetiology is still 
unclear, but it is known that the symptoms are caused by swelling and 
inflammation of the facial nerve. Eye protection remains crucial in 
preventing long-term eye complications.  
 
Drug treatment is controversial, given that over 70% of patients will 
eventually recover normal facial function without treatment. Early treatment 
with prednisolone can hasten recovery and reduce long-term sequelae. 
Although the quality of evidence is low to moderate, there may be some 
benefit in adding antiviral drugs to prednisolone.13 It is however, important 
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to discuss the harms and benefits with patients, given the potential adverse 
effects of prednisolone and antiviral drugs.  
Articles in Progress/Sullivan/Changes after EEC 315 (JD) 10 
 
REFERENCES 
1. De Diego-Sastre JI, Prim-Espada MP, Fernández-García F. [The 
epidemiology of Bell’s palsy]. Rev Neurol 2005;41:287-90. PubMed 
2. Adour K, Wingerd J, Doty HE. Prevalence of concurrent diabetes mellitus 
and idiopathic facial paralysis (Bell's palsy). Diabetes 1975;24:449-51. 
3. Linder T, Bossart W, Bodmer D. Bell’s palsy and Herpes simplex virus: 
fact or mystery? Otol Neurotol 2005;26:109-13. PubMed 
http://dx.doi.org/10.1097/00129492-200501000-00020 
4. Murakami S, Mizobuchi M, Nakashiro Y, Doi T, Hato N, Yanagihara N. 
Bell palsy and herpes simplex virus: identification of viral DNA in 
endoneurial fluid and muscle. Ann Intern Med 1996;124:27-30. PubMed 
http://dx.doi.org/10.7326/0003-4819-124-1_Part_1-199601010-00005 
5. Seok JI, Lee DK, Kim KJ. The usefulness of clinical findings in localising 
lesions in Bell’s palsy: comparison with MRI. J Neurol Neurosurg 
Psychiatry 2008;79:418-20. Epub 2007 Jun 5. PubMed 
http://dx.doi.org/10.1136/jnnp.2007.118489 
6. Peitersen E. Bell’s palsy: the spontaneous course of 2,500 peripheral 
facial nerve palsies of different etiologies. Acta Otolaryngol Suppl 
2002;549:4-30. PubMed 
http://dx.doi.org/10.1080/000164802320401694 
7. Sullivan FM, Swan IR, Donnan PT, Morrison JM, Smith BH, McKinstry 
B, et al. Early treatment with prednisolone or acyclovir in Bell’s palsy. N 
Engl J Med 2007;357:1598-607. PubMed 
http://dx.doi.org/10.1056/NEJMoa072006  
8. Sullivan FM, Swan IR, Donnan PT, Morrison JM, Smith BH, McKinstry 
B, et al. A randomised controlled trial of the use of aciclovir and/or 
prednisolone for the early treatment of Bell’s palsy: the BELLS study. 
Health Technol Assess 2009;13:iii-iv, ix-xi 1-130.  
9. Scottish Bell's palsy study [Internet]. 
http://www.scottishbellspalsy.info/ [cited 2016 Sept 13] 
10. Tojima H, Aoyagi M, Inamura H, Maeyama H, Kohshu H, Tada Y, et al. 
Management of Bell’s palsy accompanied by diabetes. Eur Arch 
Otorhinolaryngology 1994;S509-11. 
Articles in Progress/Sullivan/Changes after EEC 315 (JD) 11 
 
11. Madhok VB, Gagyor I, Daly F, Somasundara D, Sullivan M, Gammie F, 
et al. Corticosteroids for Bell’s palsy (idiopathic facial paralysis). 
Cochrane Database Syst Rev 2016;7:CD001942. PubMed 
12. Hato N, Yamada H, Kohno H, Matsumoto S, Honda N, Gyo K. et al, 
Valacyclovir and prednisolone treatment for Bell’s palsy: a multicentre, 
randomized, placebo-controlled study. Otol Neurotol 2007;28:408-13. 
13. Allen D, Dunn L. Aciclovir or valaciclovir for Bell’s palsy (idiopathic facial 
paralysis). Cochrane Database Syst Rev 2004;3:CD001869. PubMed 
14. Gagyor I, Madhok VB, Daly F, Somasundara D, Sullivan M, Gammie F, 
et al. Antiviral treatment of Bell’s palsy (idiopathic facial paralysis). 
Cochrane Database Syst Rev 2015;11:CD001869. 
doi:10.1002/14651858.CD001869.pub8. 
http://dx.doi.org/10.1002/14651858.CD001869.pub8 
15. de Almeida JR, Al Khabori M, Guyatt GH, Witterick IJ, Lin VY, Nedzelski 
JM, et al. Combined corticosteroid and antiviral treatment for Bell palsy: 
a systematic review and meta-analysis. JAMA 2009;302:985-93. PubMed 
http://dx.doi.org/10.1001/jama.2009.1243 
16. Lee HY, Byun JY, Park MS, Yeo SG. Steroid-antiviral treatment improves 
the recovery rate in patients with severe Bell's palsy. Am J Med 
2013;126:336-41. doi: 10.1016/j.amjmed. 2012.08.020. Epub 2013 Feb 
6. 
17. Gronseth GS, Paduga R; American Academy of Neurology. Evidence-
based guideline update: steroids and antivirals for Bell palsy: report of 
the Guideline Development Subcommittee of the American Academy of 
Neurology. Neurology 2012;79:2209-13. PubMed 
http://dx.doi.org/10.1212/WNL.0b013e318275978c 
18. Research Data Australia [Internet]. Bell’s palsy in children (BellPIC) 
[2015-2020]. Australian National Data Service.  
https://researchdata.ands.org.au/bells-palsy-children-bellpic/518554 
[cited 2016 Dec 07] 
19. Teixeira LJ, Valbuza JS, Prado GF. Physical therapy for Bell’s palsy 
(idiopathic facial paralysis). Cochrane Database Syst Rev 
2011;12:CD006283. PubMed 
Articles in Progress/Sullivan/Changes after EEC 315 (JD) 12 
 
20. McAllister K, Walker D, Donnan PT, Swan I. Surgical interventions for 
the early management of Bell’s palsy. Cochrane Database Syst Rev 
2013;10:CD007468. 10.1002/14651858.CD007468.pub3 PubMed 
21. Grogan PM, Gronseth GS. Practice parameter: Steroids, acyclovir, and 
surgery for Bell’s palsy (an evidence-based review): report of the Quality 
Standards Subcommittee of the American Academy of Neurology. 
Neurology 2001;56:830-6. PubMed 
http://dx.doi.org/10.1212/WNL.56.7.830 
22. de Almeida JR, Guyatt GH, Sud S, Dorion J, Hill MD, Kolber MR, et al.; 
Bell Palsy Working Group, Canadian Society of Otolaryngology - Head 
and Neck Surgery and Canadian Neurological Sciences Federation. 
Management of Bell palsy: clinical practice guideline. CMAJ 
2014;186:917-22. http://dx.doi.org/10.1503/cmaj.131801 PubMed 
  
Articles in Progress/Sullivan/Changes after EEC 315 (JD) 13 
 
Box Clinical features 
___________________________________________________________________________ 
Symptoms and signs can vary from mild to severe. The presentations 
include: 
 
• Weakness or paralysis of the upper and lower facial muscles of the 
affected side 
• Drooping of ipsilateral eyelids 
• Inability to close the eye completely 
• Drooping of the corner of the mouth 
• Dry eye due to inability to close eyes completely 
• Excessive tearing of the eye (epiphora) 
• Ipsilateral impaired/loss of taste sensation 
• Difficulty with eating due to ipsilateral muscle weakness causing food 
to be trapped on the affected side of the mouth 
• Dribbling of saliva 
• Pain in or behind the ear 
• Altered sensation on the affected side of the face 
• Increased sensitivity to sound (hyperacusis) on affected side if 
stapedius muscle is involved (Fig.).  
 
__________________________________________________________________________ 
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Fig. Possible symptoms of Bell’s palsy 
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